Open Orphan PLC Upcoming Scientific Presentations
27 September 2022 - 04:02PM
RNS Non-Regulatory
TIDMORPH
Open Orphan PLC
27 September 2022
Open Orphan plc
("Open Orphan" or the "Company")
Upcoming Scientific Presentations
Open Orphan plc (AIM: ORPH), (to be renamed hVIVO plc (AIM: HVO)
effective 26 October 2022), a rapidly growing specialist contract
research organisation (CRO) and world leader in testing infectious
and respiratory disease products using human challenge clinical
trials, announces that three presentations discussing the data and
learnings from recent clinical studies and projects will be
presented at two upcoming conferences taking place in Belfast,
Northern Ireland.
OPTIONS XI for the Control of Influenza is being held 26 - 29
September 2022 and hVIVO will be at booth 6 during the conference
for potential partnering discussions. The 12 (th) International RSV
Symposium will take place on 29 September to 2 October 2022 and
hVIVO will be at booth 6 during the conference for potential
partnering discussions.
Details of the presentations at OPTIONS XI for the Control of
Influenza are as follows:
Title: Immunomodulators and treatment of disease in the influenza
human challenge model
Abstract: AOXI0665
Date: Wednesday, 28 September 2022
Location: Hall 1, Poster Board Number: P-532
Title: Influenza, COVID-19, RSV and HRV: translating efficacy testing
of vaccine and drugs from human challenge models to the field
Abstract: AOXI0658
Date: Thursday, 29 September 2022 at 11:12 AM
Session: Oral Abstract Session: Translational: Influenza & COVID-19
- Human challenge models
Details of the presentation at the 12(th) International RSV
Symposium are as follows:
Title: RSV vaccines/prophylactics: key learnings from the RSV challenge
model and Efficacy of Vaccines
Abstract: ARNI0259
Date: Friday, September 30, 2022
The abstracts and posters will be available on hVIVO's website
from 4 October 2022 here .
For further information please contact:
Open Orphan plc +44 (0) 20 7756 1300
Yamin Khan, Chief Executive Officer
Walbrook PR (Financial PR & IR) +44 (0) 20 7933 8780 or openorphan@walbrookpr.com
Stephanie Cuthbert / Phillip +44 (0) 7796 794 663 / +44 (0) 7867 984
Marriage / 082 /
Louis Ashe-Jepson +44 (0) 7747 515 393
Notes to Editors
Open Orphan plc (London and Euronext: ORPH) is changing its name
to hVIVO plc (AIM and Euronext: HVO), which is expected to take
effect on the AIM market of the London Stock Exchange and the
Euronext Growth Exchange market on 26 October 2022.
hVIVO is a rapidly growing contract research company that is a
world leader in testing infectious and respiratory disease products
using human challenge clinical trials. The Company provides
services to Big Pharma, biotech, and government/public health
organisations.
The Company has a leading portfolio of human challenge study
models for infectious and respiratory diseases and is developing a
number of new models, such as malaria and COVID-19, to address the
dramatic growth of the global infectious disease market. The Paris
and Breda offices have over 25 years of experience providing drug
development services such as biometry, data management, statistics
CMC, PK and medical writing to third party clients as well as
supporting the London-based challenge studies.
hVIVO runs challenge studies in London from its Whitechapel
quarantine clinic, its state-of-the-art QMB clinic with its highly
specialised on-site virology and immunology laboratory, and its
newly opened clinic in Plumbers Row. To recruit volunteers /
patients for its studies, the Company leverages its unique clinical
trial recruitment capacity via its FluCamp volunteer screening
facilities in London and Manchester. The newly opened facilities
have expanded the scope of the business to enable the offering of
Phase I and Phase II vaccine field trials, PK studies, bridging
studies, and patient trials as part of large international
multi-centre studies.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAPPURCBUPPGQQ
(END) Dow Jones Newswires
September 27, 2022 02:02 ET (06:02 GMT)
Hvivo (LSE:HVO)
Historical Stock Chart
From Feb 2024 to Mar 2024
Hvivo (LSE:HVO)
Historical Stock Chart
From Mar 2023 to Mar 2024